Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AMR report depicts industry commitment

Executive Summary

Medicines for Europe is among the healthcare industry stakeholders who have welcomed the first report on antimicrobial resistance (AMR) by the AMR Industry Alliance, which “brings together over 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and trade associations from 20 countries” and shows that “broadly the Alliance membership is already active and making positive contributions to the challenge of AMR”.

You may also be interested in...



Generics Industry Must Play ‘Crucial Role’ In AMR Industry Alliance

Generics firms have a crucial role to play in the fight against antimicrobial resistance, Thomas Cueni, chair of the AMR Industry Alliance, tells Generics Bulletin in an exclusive interview.

Clinical Trial Diversity Would Benefit From Regulatory, Financial Incentives, Experts Say

Access to expedited regulatory pathways, marketing exclusivity and tax credits in exchange for enrolling and retaining diverse clinical trial populations could provide a ‘carrot’ to the ‘stick’ in US FDA guidance and legislative proposals; attorneys Sarah Thompson Schick and Winston Kirton also call for a re-examination of concerns about remuneration for trial participants.

Could US FDA Move Gene Therapy Regulation To Device Center In Years To Come?

CBER Director Peter Marks said more sophisticated manufacturing expected in the next decade could lead to questions about whether gene therapies should be regulated by his center or CDRH.

Latest News
See All
UsernamePublicRestriction

Register

GB000240

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel